• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

含有纤溶酶原激活位点的环肽的合成与性质

Synthesis and properties of cyclic peptides containing the activation site of plasminogen.

作者信息

Ganu V S, Shaw E

出版信息

Int J Pept Protein Res. 1982 Nov;20(5):421-8. doi: 10.1111/j.1399-3011.1982.tb03062.x.

DOI:10.1111/j.1399-3011.1982.tb03062.x
PMID:7174205
Abstract

The activation of plasminogen results from proteolytic cleavage of the Arg560-Val561 bond by plasminogen activators (Sottrup-Jensen et al. PNAS (1975) 72, 2577). This region of the zymogen occurs in a small disulfide loop that must restrict the conformation around this bond. The nonapeptide sequence NH2-Cys-Pro-Gly-Arg-Val-Val-Gly-Gly-Cys-NH2 of plasminogen containing the activator sensitive arginyl valine bond was synthesized by carbodiimide coupling of Boc-Cys-Pro-Gly-OH(S-4-methylbenzyl) to NH2-Arg(NO2)-Val-Val-Gly-Gly-Cys-NH2(S-4-methylbenzyl), followed by HF treatment and K3Fe(CN)6 oxidation to form a disulfide bond. Purified peptide was not a substrate for urokinase (UK) or plasminogen activator (PA) but possessed a slightly inhibitory activity towards PA. Addition of a lysine to the N-terminus of the nonapeptide yielded a decapeptide sequence of plasminogen that was a better substrate for UK but not for PA. The decapeptide inhibits PA slightly but not UK. These results suggest that active site geometry for PA must be more restrictive than that of UK and that other regions may be involved in the productive interactions with the activators inducing a better fit of the cyclic peptide loop.

摘要

纤溶酶原的激活是由纤溶酶原激活剂对精氨酸560 - 缬氨酸561键进行蛋白水解切割而产生的(索特鲁普 - 延森等人,《美国国家科学院院刊》(1975年)72卷,2577页)。该酶原的这一区域存在于一个小的二硫键环中,这个环必定会限制该键周围的构象。通过将Boc - Cys - Pro - Gly - OH(S - 4 - 甲基苄基)与NH2 - Arg(NO2) - Val - Val - Gly - Gly - Cys - NH2(S - 4 - 甲基苄基)进行碳二亚胺偶联,随后进行氢氟酸处理和铁氰化钾氧化以形成二硫键,合成了含有激活剂敏感的精氨酰缬氨酸键的纤溶酶原九肽序列NH2 - Cys - Pro - Gly - Arg - Val - Val - Gly - Gly - Cys - NH2。纯化后的肽不是尿激酶(UK)或纤溶酶原激活剂(PA)的底物,但对PA具有轻微的抑制活性。在九肽的N端添加一个赖氨酸得到了纤溶酶原的十肽序列,该序列是UK更好的底物,但不是PA的底物。该十肽对PA有轻微抑制作用,但对UK没有抑制作用。这些结果表明,PA的活性位点几何结构比UK的更具限制性,并且其他区域可能参与与激活剂的有效相互作用,从而使环状肽环的契合度更好。

相似文献

1
Synthesis and properties of cyclic peptides containing the activation site of plasminogen.含有纤溶酶原激活位点的环肽的合成与性质
Int J Pept Protein Res. 1982 Nov;20(5):421-8. doi: 10.1111/j.1399-3011.1982.tb03062.x.
2
Amino acids and peptides. XXVII. Solid phase synthesis of fibrinogen-related peptides with disulfide bond formed on solid support.氨基酸与肽。XXVII。在固相载体上形成二硫键的纤维蛋白原相关肽的固相合成。
Chem Pharm Bull (Tokyo). 1996 May;44(5):1107-10. doi: 10.1248/cpb.44.1107.
3
Structural and functional characterization of mutants of recombinant single-chain urokinase-type plasminogen activator obtained by site-specific mutagenesis of Lys158, Ile159 and Ile160.通过对赖氨酸158、异亮氨酸159和异亮氨酸160进行位点特异性诱变获得的重组单链尿激酶型纤溶酶原激活剂突变体的结构和功能表征。
Eur J Biochem. 1988 Nov 15;177(3):575-82. doi: 10.1111/j.1432-1033.1988.tb14409.x.
4
Aggregation of washed platelets by plasminogen and plasminogen activators is mediated by plasmin and is inhibited by a synthetic peptide disulfide.纤溶酶原和纤溶酶原激活剂对洗涤血小板的聚集作用由纤溶酶介导,并被一种合成肽二硫化物所抑制。
Thromb Res. 1992 Mar 1;65(4-5):533-47. doi: 10.1016/0049-3848(92)90204-n.
5
Synthesis of a cyclic analogue of the C-loop region of epidermal growth factor, containing 1-aminocyclopropane-1-carboxylic acid.含1-氨基环丙烷-1-羧酸的表皮生长因子C环区域环状类似物的合成。
Int J Pept Protein Res. 1994 Mar;43(3):225-9. doi: 10.1111/j.1399-3011.1994.tb00384.x.
6
High-resolution NMR studies of fibrinogen-like peptides in solution: structural basis for the bleeding disorder caused by a single mutation of Gly(12) to Val(12) in the A alpha chain of human fibrinogen Rouen.溶液中纤维蛋白原样肽的高分辨率核磁共振研究:人纤维蛋白原鲁昂Aα链中Gly(12)突变为Val(12)的单一突变导致出血性疾病的结构基础。
Biochemistry. 1989 Apr 4;28(7):3106-19. doi: 10.1021/bi00433a054.
7
Amino acid sequence of human tumor derived angiogenin.人类肿瘤衍生血管生成素的氨基酸序列。
Biochemistry. 1985 Sep 24;24(20):5486-94. doi: 10.1021/bi00341a031.
8
Characterization of the intrinsic fibrinolytic properties of pro-urokinase through a study of plasmin-resistant mutant forms produced by site-specific mutagenesis of lysine(158).通过对赖氨酸(158)位点特异性诱变产生的抗纤溶酶突变体形式的研究,对尿激酶原的内在纤溶特性进行表征。
J Clin Invest. 1988 Dec;82(6):1956-62. doi: 10.1172/JCI113815.
9
Substrate specificity of tissue-type and urokinase-type plasminogen activators.组织型和尿激酶型纤溶酶原激活剂的底物特异性。
Biochem Biophys Res Commun. 1991 Jan 31;174(2):432-8. doi: 10.1016/0006-291x(91)91434-e.
10
The behaviour of urokinase and porcine kidney cell plasminogen activator towards some synthetic peptides.尿激酶和猪肾细胞纤溶酶原激活物对某些合成肽的作用。
Thromb Res. 1984 Apr 15;34(2):103-7. doi: 10.1016/0049-3848(84)90066-5.

引用本文的文献

1
Structure and function of microplasminogen: II. Determinants of activation by urokinase and by the bacterial activator streptokinase.微纤溶酶原的结构与功能:II. 尿激酶和细菌激活剂链激酶激活的决定因素
Protein Sci. 1995 Sep;4(9):1768-79. doi: 10.1002/pro.5560040912.